Insider Selling: Scholar Rock (NASDAQ:SRRK) COO Sells 16,746 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) COO Keith Woods sold 16,746 shares of the business’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total transaction of $715,054.20. Following the transaction, the chief operating officer owned 583,254 shares in the company, valued at $24,904,945.80. This trade represents a 2.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Scholar Rock Trading Up 2.1%

Shares of Scholar Rock stock traded up $0.95 during trading on Thursday, hitting $46.53. The stock had a trading volume of 988,383 shares, compared to its average volume of 911,044. Scholar Rock Holding Corporation has a 12 month low of $22.71 and a 12 month high of $48.28. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30. The firm’s fifty day simple moving average is $42.02 and its 200-day simple moving average is $36.87. The stock has a market cap of $4.75 billion, a PE ratio of -14.77 and a beta of 0.63.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period in the prior year, the firm earned ($0.66) EPS. As a group, sell-side analysts expect that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on SRRK shares. Wolfe Research initiated coverage on Scholar Rock in a research report on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 price objective on the stock. Citigroup started coverage on shares of Scholar Rock in a research note on Friday, January 9th. They set a “buy” rating and a $55.00 target price for the company. Barclays raised their price target on shares of Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a research report on Wednesday, October 8th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $50.14.

Institutional Trading of Scholar Rock

Hedge funds have recently added to or reduced their stakes in the business. Moody Aldrich Partners LLC increased its position in Scholar Rock by 53.5% during the 3rd quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock valued at $3,789,000 after purchasing an additional 35,481 shares during the period. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. boosted its stake in shares of Scholar Rock by 145.3% during the second quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 769,442 shares of the company’s stock valued at $27,254,000 after purchasing an additional 455,753 shares in the last quarter. Norges Bank purchased a new position in Scholar Rock during the second quarter valued at approximately $41,628,000. Voya Investment Management LLC raised its stake in Scholar Rock by 18.1% in the third quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock worth $16,503,000 after buying an additional 67,839 shares in the last quarter. Finally, Intech Investment Management LLC raised its stake in Scholar Rock by 60.9% in the first quarter. Intech Investment Management LLC now owns 56,784 shares of the company’s stock worth $1,826,000 after buying an additional 21,483 shares in the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).